This clinical study aimed to provide awareness of the teriparatide injection and also prevention of unwanted events.
The 72 cases aged between 52-69 with the inclusion criteria: back pain proved by the x-ray with one or more collapsed spines,
no underlying diseases and no history of bone tumor, hyperparathyroid, hypercalcemia. The blood screening for renal, liver
profiles, uric acid, mineral profile and bone turnover markers (bCTx, PINP) are used as 6-month monitor. The results
showed that the common unwanted effects were hypercalcemia, hyperuricemia, hypomagnesia: 5.5 %, 54.56% and 43%
respectively at the first month of the therapy. At the end of 6th month, these conditions occurred 1.38%, 8.77% and 5.5%
respectively. The bone turnover markers, PINP, was a quick response in the first month, the PINP was double increased then
triple increased at the end of the 6th month (p = 0.001). Teriparatide did not disturb the activity of parathyroid glands because
the PTH was within the normal limit during the treatment (p = 0.001). The blood screening monitor was useful for preventing
the unwanted effects and the bone turnover markers, PINP, was beneficial for evaluation of Teriparatide efficacy in short
outcomes leading to physicians and patients’ confidence.

Keywords: Teriparatide, Bone markers, PTH